Mounjaro denial: how to appeal a tirzepatide (diabetes) denial

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Most denials are prior-authorization or step-therapy denials on the diabetes benefit, which are frequently winnable with documentation. A weight-loss prescription is off-label for Mounjaro — Zepbound is the tirzepatide approved for chronic weight management — so a weight-loss appeal is weaker than a diabetes one.

How Mounjaro is covered

On the diabetes benefit, plans typically require a documented type 2 diabetes diagnosis, an A1c, and often a step-therapy trial of metformin or a preferred agent. Coverage for weight loss is not supported by Mounjaro's FDA label.

Why Mounjaro claims get denied

• Prior authorization missing for a drug that requires it.
• Step therapy: metformin or a preferred GLP-1/GIP wasn't tried or documented.
• The type 2 diabetes diagnosis or A1c wasn't documented to criteria.
• Prescribed for weight loss — off-label for Mounjaro.
• Quantity limits exceeded.

Is a Mounjaro denial worth appealing?

How to appeal a Mounjaro denial

1. 1

   Establish the diabetes indication

   Attach the type 2 diabetes diagnosis and a recent A1c — the basis for a coverable Mounjaro claim.

2. 2

   Clear step therapy

   Document the trial/failure or intolerance/contraindication of metformin or the plan's preferred agent.

3. 3

   Redirect a weight-loss request

   If the intent is weight management, the on-label tirzepatide is Zepbound; appeal Mounjaro only on the diabetes indication.

Mounjaro — frequently asked

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.